A keto-carotenoid
The systematic name is 3,3′-dihydroxy-β,β′-carotene-4,4′-dione. That already states the structure: a β-carotene skeleton, a hydroxyl at each 3 position, a ketone at each 4.
Kuhn and Lederer isolated the red pigment from crayfish in 1933; Kuhn and Sørensen worked out the
structure and named it in 1938. The first half of astaxanthin comes from
Astacus, the crayfish genus; the second half is Greek xanthos, yellow.
The name records where it was first found: a boiled shell.
Lobsters do not make it. They take it from food, store it in shell and tissue, and pass it up the food chain. The actual producers are algae and microbes. Humans cannot synthesise it either.
- Formula
- C40H52O440 carbons, 4 oxygens
- Molecular weight
- 596.84High end for a carotenoid
- CAS
- 472-61-7For standards and regulatory lookups
- C=C bonds
- 13Sets colour and antioxidant activity
β-Carotene is pure hydrocarbon. Astaxanthin opens two oxygen gates at each end. Every difference in what follows comes back to those four oxygens.
What the shape allows
A hydroxyl at C3 and a ketone at C4 turn a hydrophobic rod into an amphiphile: water-loving at both ends, oily in the middle.
β-Carotene is a conjugated polyene chain capped at both ends by a β-ionone ring, and those rings carry nothing but carbon and hydrogen. The molecule is hydrophobic end to end, so it stays inside the hydrophobic core of a membrane and never reaches the water-facing side.
Astaxanthin modifies the same two rings: a hydroxyl (–OH) at C3, a ketone (=O) at C4, symmetrical on both sides. Both groups are polar, so the molecule becomes amphiphilic. The central chain buries itself in the membrane while the two polar ends reach the surface and touch water. At roughly 30 Å long it matches the thickness of a lipid bilayer.
So it stands upright, spanning the bilayer end to end, both terminals exposed at the water interfaces. It can reach radicals inside the membrane and at its surface. Other carotenoids cannot.
The last two steps
From IPP to β-carotene runs the highway every carotenoid shares. Astaxanthin branches off in the last two reactions, one after the other.
β-Carotene
C40H56Built from GGPP through phytoene and lycopene by desaturation and cyclisation. The hub of the whole pathway.
Zeaxanthin
C40H56O2A hydroxyl at each end; polarity appears. Also reachable stepwise through β-cryptoxanthin.
Astaxanthin
C40H52O4One more ketone at each end completes the amphiphile. The conjugated system extends and the colour shifts from orange to red.
A bypass exists too. CrtW can ketolate β-carotene to canthaxanthin first, then CrtZ hydroxylates it, arriving at the same place. Both routes run in vivo at once, and the ratio depends on the relative activity and substrate affinity of the two enzymes. That is exactly what makes heterologous expression hard to tune.
CrtW (β-carotene ketolase) and CrtZ (β-carotene hydroxylase) both belong to the non-heme iron oxygenase family. They need iron, molecular oxygen and reducing power. Enzymes from different sources are not interchangeable: those from marine bacteria, Paracoccus and Haematococcus differ sharply in substrate preference, specific activity and optimum temperature. Swap the source and titre can move by an order of magnitude.
The pathway is known. What stalls is enzyme efficiency. Hunting for enzymes means hunting here.
Different sources, different isomers
Astaxanthin comes in three stereoisomeric forms: 3S,3′S, 3R,3′R and 3R,3′S (meso). The main product depends on the source, and configuration affects bioavailability and pigmentation.
| Source | Type | Typical level | Main isomer | Commercial role |
|---|---|---|---|---|
| Haematococcus pluvialis | Microalga | 1.5–4% of DW | 3S,3′S | Natural mainstream |
| Xanthophyllomyces dendrorhous | Yeast | Usually much lower | 3R,3′R | Secondary route |
| Chemical synthesis | Industrial | High purity, low cost | Mixed isomers | Mostly feed grade |
| Crustacean by-products | Waste recovery | Low content, hard to extract | Mostly 3S,3′S | Resource recovery |
3S,3′S matters because it is the form found in animals. It is what you detect in shrimp, crab and salmon. Mismatch the configuration and both binding efficiency and deposition rate fall. That is the technical reason algal sources command a premium, and it is not all marketing.
High content does not mean it is ready to use. As H. pluvialis accumulates astaxanthin its wall thickens into an aplanospore. Without breaking it, solvent cannot get in. Cell disruption is another cost and stability hurdle.
Why it outperforms the others
Two mechanisms stack: the conjugated chain quenches singlet oxygen, the polar ends scavenge radicals at the membrane interface, and the spanning posture lets both happen at once.
A qualitative ranking to show relative order, not a fold change under any particular assay.
Mechanism one: singlet oxygen quenching. The electron system of the conjugated chain takes energy from singlet oxygen, drops it back to ground state, and returns to ground state itself without being consumed. This is physical quenching, and it repeats.
Mechanism two: radical scavenging. The chain hands an electron or a hydrogen to a lipid peroxyl radical, breaking the chain reaction. Here the molecule itself is consumed or degrades, so this is chemical protection.
This is where holding both positions pays off: radicals at the surface are handled on the spot by the polar ends, while peroxidation running inside the membrane is intercepted by the chain. β-Carotene can only do the second.
Where the boundary sits: these mechanisms are well supported in vitro and in cell models. Between in vitro antioxidant capacity and an effect in humans lie absorption, distribution, metabolism and dose. Quoting a test-tube number as a human benefit is the most common error made about this class.
The biggest market is not supplements
Astaxanthin is usually sold as an anti-ageing supplement. The largest volume by far goes to colouring farmed animals.
Aquaculture pigmentation
The orange-red muscle of salmon and the red of shrimp shells come from astaxanthin in feed. Farmed animals cannot make it; without it they go pale.
The single largest use worldwide, and the most price-sensitive feed-grade market.
Poultry and yolk colour
Used to deepen yolk and skin colour. A feed colourant function that runs alongside the antioxidant one.
Food and supplements
Algal astaxanthin is approved as a new food raw material in China. Products are mostly algal powder and oil capsules.
Limits and labelling follow current announcements.
Cosmetics
Used in anti-photoageing and antioxidant formulas. Topical use runs into stability: light and oxygen both accelerate degradation.
Medical research
Clinical work exists in skin photoprotection, post-exercise recovery, blood lipids and the retina, but sample sizes are generally small and conclusions vary in strength.
Stability is the common problem
Sensitive to light, heat and oxygen, prone to isomerisation and degradation. Industry microencapsulates as standard, and the encapsulation is itself a barrier to entry.
Why it costs this much
The structure is not complicated. The hard part is getting cells to make a lot of it, then getting it out intact.
- Two-stage cultivation First grow biomass under full nutrition, then switch to high light and nitrogen starvation to push carbon into astaxanthin. The two stages want opposite conditions, and the timing of the switch sets final yield.
- Slow growth, easy contamination H. pluvialis has a long doubling time. Open ponds pick up bacteria and competing algae, and one contamination ruins the batch. Closed photobioreactors control this at high capital cost.
- Breaking the spore wall The wall thickens as astaxanthin accumulates. No disruption, no extraction. Disruption is energy-hungry, and harsh conditions degrade the product.
- Extraction and purification Astaxanthin is strongly lipophilic, so organic solvents or supercritical CO2 are standard. Solvent residue, recovery rate and isomerisation each add cost.
- Storage and formulation Light, heat and oxygen all degrade or isomerise it, so encapsulation, light protection and nitrogen blanketing are mandatory. Those costs land in the final price.
Synthetic feed-grade astaxanthin undercuts natural extraction by a wide margin, which is why it still holds the feed market. The premium on natural sources comes from configuration and consumer perception, not purity.
Moving the pathway into other cells
The pathway is mapped and the enzymes are available. So why not skip the algae and let engineered bacteria do it? Products exist, but a few bottlenecks keep biting.
The idea is to put the upstream carotenoid skeleton genes and CrtW/CrtZ into a heterologous host. E. coli, S. cerevisiae and Yarrowia lipolytica have all been tried. Y. lipolytica looks most promising because it accumulates lipid and gives hydrophobic products somewhere to sit.
- Bottleneck one: activity and match CrtW and CrtZ from different species do not keep the same rhythm. Intermediates pile up or bypass products dominate. You screen them as pairs, not as individual high-activity hits.
- Bottleneck two: precursor supply The carotenoid pathway draws on IPP and GGPP, which compete with sterol and ubiquinone synthesis for the same carbon pool. Without upstream engineering, titre does not move.
- Bottleneck three: product toxicity Astaxanthin and its intermediates damage membrane structure once they build up past a threshold, and growth stalls. Efflux and compartmentalisation are not optional.
- Bottleneck four: reducing power and oxygen CrtW/CrtZ are oxygenases needing iron, O2 and reducing equivalents. Supplying oxygen and holding redox balance are hard to satisfy at once in high-density fermentation.
The enzymes are known. The pathway is known. The hard part is making the whole set of reactions run smoothly in a new host at the same time. Which is why enzyme hunting and module building have to happen together.
Four claims that travel well
None of these was invented from nothing. Each lost its qualifiers somewhere along the way.
Where to go next
No reading list. Search strings instead. Reviews change every year and links rot; queries do not.
Search along three separate threads: chemistry and antioxidant mechanism, synthetic-biology titre work, and human clinical evidence. Quality differs enormously between them, and reading them together lets weak clinical work skew your picture.
Check volume, issue and pages before you cite. The classic reviews here get re-cited endlessly, and wrong years and volume numbers are common in secondhand citations. Resolve the DOI or PMID back to the original; do not copy someone else's reference list.